Loading patent…
AssigneeNovartis AG
InventorsSouvik BHATTACHARYA, Bruno BIETH, Maciej CABANSKI, Bruno CENNI, Stefan DE BUCK, Martin KAUL, Arvind KINHIKAR, Andrijana RADIVOJEVIC, Thomas SEVERIN, Julian STORIM, Alessandra VITALITI GARAMI
Estimating the term…
The present disclosure relates to methods for treating Chronic Spontaneous Urticaria using a compound of Formula (I) or a pharmaceutically acceptable salt thereof. Also disclosed herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, for treating Chronic Spontaneous Urticaria patients, as well as medicaments, dosing regimens, pharmaceutical formulations, dosage forms, and kits for use in the disclosed uses and methods.
A compound of Formula (I):
The compound of Formula (I), or a pharmaceutically acceptable salt thereof, for use according to any of the preceding claims, wherein, prior to treatment with the compound of Formula (I), the subject has been previously treated with a systemic agent for CSU.
The compound of Formula (I), or a pharmaceutically acceptable salt thereof, for use according to any of the preceding claims, wherein the subject has moderate to severe CSU.
The compound of Formula (I), or a pharmaceutically acceptable salt thereof, for use according to any of the preceding claims, wherein the subject is an adult.
The compound of Formula (I), or a pharmaceutically acceptable salt thereof, for use according to any one of the preceding claims, wherein said subject achieves by week 4 or at week 12 of treatment at least one of the following:
The compound of Formula (I), or a pharmaceutically acceptable salt thereof, for use according to any of preceding claims, wherein said subject achieves a sustained response as measured by complete hives and itch response ([UAS7]=0) and/or a Dermatology Life Quality Index (DLQI)=0−1 and/or a continued absence of angiodema (AAS7=0) at week 4 after completion of the treatment.
The compound of Formula (I) or a pharmaceutically acceptable salt thereof, for use according to any of the preceding claims, wherein the compound of Formula (I), or pharmaceutically acceptable salt thereof is disposed in a pharmaceutical formulation and wherein said pharmaceutical formulation further comprises pharmaceutically acceptable carriers.
Dependencies are inferred from the claim text.